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SELF-RELATED HEALTH AND BLOOD HYPERCOAGULABILITY:  A POSSIBLE MECHANISM FOR 
CARDIOVASCULAR RISK ? 
 
Gordon D O Lowe 
Emeritus Professor, Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK 
 
Low self-related health (SRH) is one, single-item, measure of low chronic general health. SRH has 
been shown to be a predictor of total mortality and of cardiovascular  mortality in prospective 
studies of generally healthy populations (1-3).  Several factors influence SRH scores, including 
medically diagnosed conditions; adverse lifestyle and other risk factors for total and cardiovascular 
mortality (including age); and individual resilience and resources to cope with declining health (4,5). 
Adjustment for major established risk factors does not, however, account for the association 
between SRH and total and cardiovascular mortality in population studies (6,7). 
Furthermore, SRH scores were also predictive of recurrent coronary heart disease (CHD) events and 
death in patients with CHD at baseline (8,9). 
Components of the haemostatic system play several roles in atherosclerosis, arterial thrombosis and 
cardiovascular disease (10-12). Several blood hypercoagulability measures, including plasma levels of 
fibrinogen, von Willebrand factor (VWF) antigen, fibrin D-dimer and tissue plasminogen activator (t-
PA) antigen are now established as risk factors for coronary heart disease, stroke and cardiovascular 
mortality in prospective studies (13-15). While plasma levels of these haemostatic factors are 
associated with several established cardiovascular risk factors (age, smoking, body mass index, blood 
pressure, cholesterol, triglycerides, and inflammatory markers), they are independently associated 
with cardiovascular risk after adjustment for these risk factors (13-15). 
The association between SRH and components of the haemostatic system has not been previously 
studied. In this issue, von Kanel and colleagues report the association of SRH with plasma levels of 
fibrinogen, VWF antigen and fibrin D-dimer with SRH scores, in 190 patients within 48 hours of an 
acute coronary intervention for acute myocardial infarction (16). SRH, before their event, was rated 
on a visual analogue scale. In fully adjusted linear regression models, SRH was inversely associated 
with plasma fibrinogen (r=-0.33), VWF (r=-0.19) and D-dimer (r=-0.25). The Global Registry of Acute 
Coronary Events (GRACE) risk score was similarly associated with these three haemostatic factors.  
The authors suggest that haemostatic activation may potentially link SRH with cardiovascular 
outcome in patients with acute coronary syndromes; because previous studies of such patients have 
reported that plasma fibrinogen, VWF and D-dimer levels are associated with risk of major CVD 
events and death up to 2 years after discharge (17-20). They also note that these and other 
haemostatic factors may be expressed during inflammation in the central nervous system (21), 
raising the possibility that they may have effects on the neural contribution to SRH scores.  
The authors acknowledge some limitations of their study. First, their subjects were a selected group 
of patients, who had satisfied the criteria for inclusion in a randomized controlled trial of the effects 
of early psychological counselling on the development of post-traumatic stress after acute 
myocardial infarction; most were men with higher education levels. They were asked to 
retrospectively score their SRH before their acute event, after their circulatory condition had 
stabilised. It is therefore possible that the acute effect influenced their recall of SRH. 
 Second, blood samples were also taken during the acute event, therefore measuring acute phase 
increments from basal levels in plasma levels of haemostatic factors (which were positively 
associated with GRACE risk scores), as well as the effects of antithrombotic treatments (although 
exploratory analyses adjusting for antithrombotic drug use did not significantly attenuate the 
associations of SRH with haemostatic factors). 
Third, this cross-sectional study did not investigate the associations between SRH, plasma levels of 
haemostatic factors and long-term outcomes after acute coronary syndromes. 
The study of von Kanel and colleagues (16) is of interest because it raises the hypothesis that 
activated haemostasis may be one potential causal mechanism for the established associations 
between low SRH and adverse cardiovascular outcomes. Further studies of this hypothesis should be 
prospective, and conducted in representative samples of both general populations and persons with 
baseline cardiovascular disease. As fibrinogen, VWF, D-dimer  and some other haemostatic factors 
are inflammatory reactants, inflammation markers such as C-reactive protein and interleukin-6 
should also be studied. While  haemostasis and antithrombotic drugs play important roles in 
cardiovascular disease and its prevention and treatment, there is increasing interest in inflammation 
and anti-inflammatory drugs in cardiovascular disease prevention (22-25). 
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